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There  has  been  growing  interest  in  disrupting  bacterial  virulence  mechanisms  as  a  form  of  infectious
disease  control  through  the  use  of  ‘anti-infective’  drugs.  Pseudomonas  aeruginosa  is  an  opportunistic
pathogen  noted  for  its intrinsic  antibiotic  resistance  that  causes  serious  infections  requiring  new  thera-
peutic  options.  In this  study,  an  analysis  of the P. aeruginosa  PAO1  deduced  proteome  was  performed  to
identify  pathogen-associated  proteins.  A  computational  screening  approach  was  then  used  to  discover
drug  repurposing  opportunities,  i.e. identifying  approved  drugs  that  bind  and potentially  disrupt  the
pathogen-associated  protein  targets.  The  selective  oestrogen  receptor  modulator  raloxifene,  a  drug  cur-
rently  used  in the  prevention  of  osteoporosis  and/or  invasive  breast  cancer  in  post-menopausal  women,
was  predicted  from  this  screen  to  bind  P.  aeruginosa  PhzB2.  PhzB2  is  involved  in production  of the  blue
pigment  pyocyanin  produced  via  the  phenazine  biosynthesis  pathway.  Pyocyanin  is  toxic  to  eukaryotic
cells  and  has  been  shown  to  play  a role  in  infection  in  a mouse  model,  making  it an  attractive  target
for  anti-infective  drug  discovery.  Raloxifene  was  found  to  strongly  attenuate  P. aeruginosa  virulence  in
a  Caenorhabditis  elegans  model  of  infection.  Treatment  of  P.  aeruginosa  wild-type  strains  PAO1  and  PA14
with  raloxifene  resulted  in a  dose-dependent  reduction  in pyocyanin  production  in vitro;  pyocyanin
production  and  virulence  were  also  reduced  for a  phzB2  insertion  mutant.  These  results  suggest  that
raloxifene  may  be  suitable  for further  development  as  a therapeutic  for P.  aeruginosa  infection  and  that
such  already  approved  drugs  may  be  computationally  screened  and  potentially  repurposed  as  novel
anti-infective/anti-virulence  agents.. Introduction
Pseudomonas aeruginosa is an opportunistic, Gram-negative
acterial pathogen that causes infections in immunocompromised
osts,  burn victims, individuals in intensive care and patients with
ystic ﬁbrosis (CF). The lungs of nearly all CF patients are chron-
cally colonised by P. aeruginosa, which signiﬁcantly reduces life
xpectancy and is the leading cause of morbidity and mortality
or CF patients. The effectiveness of P. aeruginosa as a pathogen
an be attributed to its arsenal of virulence mechanisms and its
arge metabolic capacity, including the ability to intrinsically resist
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antibiotics owing to its impermeable outer membrane, efﬂux capa-
bilities, tendency to colonise surfaces in a bioﬁlm form and ability
to acquire and maintain antibiotic plasmids [1]. Novel approaches
for the treatment of P. aeruginosa infection are urgently needed.
The  concept of targeting virulence using anti-infective/anti-
virulence drugs that ‘disarm’ pathogenic bacteria rather than kill
them has garnered increasing attention in recent years. It is
believed that such an approach places less selective pressure on
bacteria to evolve new strategies for survival, thereby being more
speciﬁc to pathogenic bacteria and subject to less selection for
drug resistance [2]. To this end, in a previous analysis we iden-
tiﬁed pathogen-associated proteins having homologues only in
pathogenic bacteria and not in non-pathogens [3]. Such proteins
are more likely to have virulence-related functions.
Open access under CC BY-NC-ND license.The list of pathogen-associated proteins identiﬁed included
components of the phenazine biosynthesis pathway. Strains of P.
aeruginosa produce and secrete a variety of redox-active phenazine
compounds, the most well studied being pyocyanin. Pyocyanin
ess under CC BY-NC-ND license.
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s responsible for the blue–green colour characteristic of Pseu-
omonas spp. and is considered both a virulence factor and a
uorum sensing (QS) signalling molecule for P. aeruginosa [4].
S-regulated virulence factors, and pyocyanin in particular, are
ctive in lung infections associated with CF and produce numer-
us effects that are relevant to CF (reviewed in [4,5]). Pyocyanin
odulates redox cycling and generates reactive oxygen species
apable of causing signiﬁcant oxidative stress, which in turn affects
alcium homeostasis [4,5]. It inhibits cellular respiration, depletes
ntracellular cAMP and ATP levels, and thus affects chloride ion
hannels that are controlled by ATP-driven conformational changes
5]. Pyocyanin inhibits prostacyclin release and can inactivate
uman V-ATPases (involved in receptor-mediated endocytosis),
1-protease inhibitor (which modulates serine protease activity,
ncluding neutrophil elastase) and nitric oxide (which inﬂuences
lood ﬂow, blood pressure and immune functions) [5]. Pyocyanin
lso alters the host immune response in several ways to aid
vasion of the immune system and establish chronic infection.
vidence suggests that pyocyanin could prevent the development
f an effective T-cell response against P. aeruginosa and prevents
he activation of monocytes and macrophages (through inhibi-
ion of cytokine production) [5]. High concentrations of pyocyanin
n the sputum of CF patients suggest that this compound plays
 role in pulmonary tissue damage observed with chronic lung
nfections, and early (in the growth curve) overexpression of QS-
egulated virulence factors such as LasA, elastase and pyocyanin
s common among populations of a highly successful CF epidemic
train [6]. Additional evidence demonstrates that pyocyanin signif-
cantly contributes to lung destruction during chronic P. aeruginosa
nfection of bronchiectasis airways in a mouse model and sup-
orts the hypothesis that pyocyanin contributes to the accelerated
ecline in lung function of CF and other bronchiectasis patients
nce they are infected with P. aeruginosa [7]. Pyocyanin biosyn-
hesis is therefore an attractive target for anti-infective drug
ntervention.
In P. aeruginosa PAO1, pyocyanin is synthesised from choris-
ate in a complex series of intermediates by enzymes encoded
y the homologous phzA1B1C1D1E1F1G1 and phzA2B2C2D2E2F2G2
perons (henceforth referred to as the phz operons) [8]. Two addi-
ional genes, phzS and phzM, convert phenazine-1-carboxylic acid
o pyocyanin in the ﬁnal steps of biosynthesis. The two  phz oper-
ns are 98.3% identical at the DNA level, with almost all of the
equence divergence occurring in the ﬁrst pair of genes, phzA1B1
nd phzA2B2. Products of the phzA and phzB genes are also homol-
gous (with ca. 67% amino acid identity).
The crystal structures for several components of the phenazine
iosynthesis pathway have been solved, making it possible to
se computational methods to help identify potential inhibitors.
 promising yet underexploited avenue for discovering new
ntimicrobials is through drug repositioning: using existing drugs
or new indications through identiﬁcation of off-target interac-
ions. Numerous screens to identify potential antimicrobials for P.
eruginosa infection using libraries of novel drug classes and bioac-
ive molecules have been conducted, but screens using libraries of
xisting approved drugs have been limited despite the obvious ben-
ﬁts of drug repositioning, i.e. existing drugs already have a clinical
istory and therefore require less time and money to develop into
 drug speciﬁc for treating a different disease. To our knowledge,
nly one study to repurpose known drugs for the treatment of P.
eruginosa infection has been reported [9].
Pseudomonas aeruginosa is a well-studied model system for
athogenesis. Genome-wide essentiality studies have provided
utant strains for its non-essential gene repertoire—tools we
an use to validate computationally predicted anti-infective tar-
ets [10–12]. There are also established infection models for P.
eruginosa, including the powerful and inexpensive Caenorhabditisimicrobial Agents 40 (2012) 246– 251 247
elegans  pathogenesis model. When P. aeruginosa strain PA14 is
grown on low-salt media, it accumulates in the C. elegans intestine,
killing the worms  relatively slowly over the course of 2–3 days.
This infection-like process referred to as ‘slow killing’ differs from
‘fast killing’ on high-osmolarity media, which involves the secre-
tion of diffusible toxins and takes place over the course of several
hours [13]. Many P. aeruginosa virulence-related genes required for
mammalian infection have been shown to play a role in C. elegans
killing, including proteins that regulate the transcription and export
of virulence factors via the type III secretion machinery as well as
proteins involved in QS [14]. Novel genes not previously known to
be involved in virulence have also been identiﬁed in this manner
[15].
Here we describe our application of drug repurposing method-
ology to identify potential anti-infective drug targets and drug
leads for P. aeruginosa. The computational screen identiﬁed poten-
tial interactions between PhzB2 from the phenazine biosynthesis
pathway and the selective oestrogen receptor modulator ralox-
ifene. We  present evidence that raloxifene attenuates P. aeruginosa
virulence and promotes C. elegans survival. A pyocyanin quantiﬁ-
cation assay demonstrated that pigment production is reduced in
the presence of raloxifene. These results suggest that raloxifene
could be a novel source of anti-infective agents for the treatment
of P. aeruginosa infection and, furthermore, that drug repurpos-
ing is a promising, efﬁcient approach for novel antimicrobial drug
discovery.
2. Materials and methods
2.1.  Database of protein–drug complexed structures
Drug repurposing uses existing approved drugs for new indi-
cations by targeting a new site or sites of interest on a protein
involved in a different disease. A database of all protein–drug com-
plexed structures was  generated by searching the RCSB Protein
Data Bank (PDB) (http://www.pdb.org) for entries having a ligand
bound to them and then cross-matching the ligand entries to the
DrugBank database [16]. Ligands in DrugBank with fewer than 10
non-hydrogen atoms, or that were known to be additives from crys-
tallographic experiments, were considered as ‘solvents’ and were
removed from the data set. DrugBank ligands that were labelled
as ‘approved’ but not considered ‘nutraceutical’ or ‘solvents’ were
retained, resulting in 1059 ligands bound to proteins with struc-
tures available in the PDB. Additional ﬁltering eliminated structures
containing DNA/RNA ligands only, C-alpha atoms only, large ribo-
somal subunits, or where the ligand was a modiﬁed residue. In total,
232 drugs are represented across 940 PDB entries. The distribution
is skewed towards drugs that are more commonly crystallised or
better studied. Detailed information on the drugs and PDB entries
can be found at http://funsite.sdsc.edu/drugome/TB/.
2.2.  Drug repurposing analysis based on ligand binding site
similarity  to identify novel drug leads
The computational drug repurposing approach applied in this
study was  based on an approach used previously to repurpose an
existing drug in treating drug-resistant tuberculosis (TB) [17], to
reconstruct TB-drugome (a structural proteome-scale drug-target
network in Mycobacterium tuberculosis), to reveal molecular mech-
anisms of anti-cancer activity of HIV protease inhibitors, and to
identify side-effect proﬁles of cholesterylester transport protein
inhibitors and oestrogen receptor modulators (reviewed in [18]).
Brieﬂy, it involves extracting the binding site of a commercially
available drug from a three-dimensional structure or model of the
target protein, identifying off-targets with similar binding sites
248 S.J.  Ho Sui et al. / International Journal of Ant
Table  1
Bacterial strains used in this study.
Strain Phenotype Reference
Escherichia coli OP50 Uracil auxotroph with
limited  growth on NGM
plates
[30]
Pseudomonas  aeruginosa PA14 Wild-type (highly virulent
clinical  isolate used as a
reference  strain; capable of
infecting multiple diverse
hosts)
[24]
PA14 phzB1 PA14 09470 transposon
mutant  (mutant ID 24980)
[11]
PA14 phzB2 PA14 39960 transposon
mutant  (mutant ID 48282)
[11]
PA14 lpxC PA14 57260 transposon
mutant  (mutant ID 34855)
[11]
P. aeruginosa PAO1 Wild-type (standard
laboratory strain and
genetic  reference strain)
[23]
PAO1 phzB1 PA4211 transposon mutant
(mutant  ID 22096)
[9]
PAO1  phzB2.1 PA1900 transposon mutant
(mutant  ID 21450)
[9]
PAO1  phzB2.2 PA1900 transposon mutant [9]
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GM, nematode growth medium.
cross the P. aeruginosa structural proteome using SMAP soft-
are [19,20], and evaluating the atomic interactions between the
utative off-targets and the drug using protein–ligand docking. A
otal of 20 targets (see Supplementary Table S1) were chosen from
n initial set of 207 P. aeruginosa proteins with structures deposited
n the PDB based on our classiﬁcation of pathogen-associated genes
3], ﬂux balance analysis with a genome-scale metabolic recon-
truction of the strain [21] and the ligand binding site similarity
etwork. These were further screened using a bidirectional BLAST
nalysis to the human genome to avoid potentially lethal side
ffects. The nine remaining targets were then subjected to the
rug repurposing approach to compare their binding sites with
hose in the protein–drug complexed database described above.
 P-value cut-off of 1e-4 for ligand binding site similarity was
sed to identify potential target–drug interactions. Docking was
erformed using Glide [22] to validate potential interactions, and
he top binding poses were manually inspected for hydropho-
ic interactions and potential hydrogen bonds. This initial study
id not consider closely related homologous structures in other
rganisms.
.3. Bacterial strains and compounds/drugs for laboratory assays
The  bacterial strains used in this study are listed in Table 1.
wo wild-type P. aeruginosa strains were studied, PAO1 [23] and
A14 [24], plus phzB1 and phzB2 transposon insertion mutants
or both strains PAO1 and PA14 [9,11]. Escherichia coli OP50
as used as a food source and non-pathogenic control for C.
legans infection studies. Raloxifene was purchased from Cay-
an Chemical (Ann Arbor, MI). Adenosine, chenodeoxycholic acid,
examethasone, oestradiol, fusidic acid, spironolactone, triﬂuop-
razine dihydrochloride, triiodothyronine (T3), trimethoprim and
hyroxine were purchased from Sigma-Aldrich Canada (Oakville,
N, Canada). The stock solution of raloxifene was prepared with
imethyl sulphoxide and oestradiol with methanol.
.4. Growth assaysStock  cultures of P. aeruginosa PAO1 and PA14 as well as the
utant strains were provided by Prof. Bob Hancock (University
f British Columbia, Vancouver, Canada). A single colony of theimicrobial Agents 40 (2012) 246– 251
bacterium  was used to inoculate 5 mL  of Luria–Bertani (LB) broth,
which was  then incubated overnight (<16 h) at 37 ◦C. A 0.3 mL
aliquot was taken from the overnight culture and transferred to
30 mL  of LB broth containing 0.1 mM of one of the approved
drugs mentioned above (or in the case of raloxifene and oestra-
diol, 100 g/mL). Growth at 37 ◦C was  monitored by absorbance at
600 nm.  Measurements were blanked with LB broth containing an
equivalent amount of the drug being tested. Growth curves were
performed a minimum of two  times.
2.5. Infection model to evaluate mutants and drugs
Caenorhabditis elegans (wild-type Bristol N2) were maintained
on nematode growth medium (NGM) plates by feeding on E. coli
OP50 lawns. Pseudomonas aeruginosa PAO1, PA14 and transposon
mutants were grown on LB culture medium. Infection of C. elegans
(L4 stage) with PAO1, PA14 or transposon mutants was performed
at 24 ◦C. Fresh NGM plates with 0.35% peptone were seeded with
bacterial cultures (50 L of overnight culture per 3.5 cm diameter
plates). The cultures were incubated at 37 ◦C overnight and were
then equilibrated at 24 ◦C for another 24 h. To minimise the con-
founding effects of progeny development, the NGM plates were
supplemented with 5-ﬂuorodeoxyuridine (100 g/mL) 1 h before
picking of worms. In each assay, 30–40 worms were transferred
onto each plate. Worms  were evaluated for viability for several
days (up to 120 h). Worms  were considered dead when they did
not move and then did not respond to touch (moving worms were
not touched to reduce stress on them). For drug assays, drugs were
incorporated at 0.1 mM on low-osmolarity NGM inoculated with
PAO1, PA14 or mutants. All experiments were performed at a min-
imum in triplicate.
2.6.  Pyocyanin production
Production  of the pyocyanin pigment was  measured using a
quantitative chemical assay. Absorbance at 520 nm in acidic solu-
tion was  measured as described by Essar et al. [25]. Brieﬂy, bacteria
from 1 mL of culture were pelleted. The supernatant containing
the pyocyanin was then extracted with 0.6 mL  of chloroform, fol-
lowed by extraction with 1 mL  of 0.2 M HCl and measurement of the
solution’s absorbance at 520 nm.  The concentration of pyocyanin
in the supernatant was expressed in g/mL by multiplying the
absorbance by 17.072.
3.  Results
3.1. Computationally predicted interactions between approved
drugs  and Pseudomonas aeruginosa drug targets
Using an efﬁcient functional site search algorithm, the bind-
ing sites of US Food and Drug Administration (FDA)-approved
drugs crystallised with their respective ligands were extracted
and compared with binding pockets on the surface of nine tar-
get proteins, including the PhzB2, PhzM and PhzS members of
the phenazine biosynthesis pathway. Within the network gener-
ated from this analysis (Fig. 1), PhzB2 met  the criteria of being
pathogen-associated (having homologues only in pathogenic bac-
teria and not in non-pathogens) and likely to be non-essential based
on transposon mutagenesis studies [9–11], making it an attractive
anti-infective drug target. PhzB1, the homologous protein in the
alternate phz operon that produces pyocyanin, was not included in
the drug repurposing analysis (and thus the drug network) because
its crystal structure had not been experimentally determined. How-
ever, it is an equally attractive target because PhzB1 and PhzB2 are
91% identical at the amino acid level, with almost all of the varia-
tion occurring in the ﬁrst 25 residues. These residues are excluded
S.J. Ho Sui et al. / International Journal of Antimicrobial Agents 40 (2012) 246– 251 249
Fig. 1. Computational drug repurposing analysis predicts interactions between
Pseudomonas  aeruginosa phenazine biosynthesis proteins and known drugs. Green
circles denote P. aeruginosa proteins labelled with gene name followed by Protein
Data  Bank structure identiﬁer in brackets. Diamonds denote known drugs pre-
dicted to interact with the P. aeruginosa proteins (identiﬁed by name and heterogen
molecule  ID in brackets), with coloured nodes indicating hormones or hormone
receptor  antagonists (darker nodes indicate oestrogenic compounds). Edges in the
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Fig. 2. Raloxifene treatment and infection with phzB1/2 mutants attenuates killing
of Caenorhabditis elegans by Pseudomonas aeruginosa PA14. (A) Survival of C. elegans
following exposure to infection with P. aeruginosa PA14 plus raloxifene at varying
doses.  The negative control is non-pathogenic Escherichia coli OP50. (B) Survival
of  C. elegans following infection with P. aeruginosa transposon insertion mutants
for  phzB1, phzB2 and lpxC versus the wild-type PA14 positive control and non-
pathogenic  E. coli OP50 negative control. (C) Growth curve for P. aeruginosa PA14
cultures with and without the presence of raloxifene as well as for P. aeruginosaraph represent signiﬁcant binding pocket similarity (using the SMAP software at
 ≤ 1e−4) to one or more existing approved drugs in the database of protein–drug
omplexed  structures that was developed (see Section 2.2).
rom the ligand binding pocket used in this analysis, making the
redicted drug interactions just as likely for PhzB1 as they are for
hzB2.
Thirteen drugs were predicted to bind to PhzB2. Each of these
as docked to the PhzB2 protein model to estimate the relative
rotein–ligand binding afﬁnities for each drug. Nine compounds
ere selected for further study based on their availability from
rug vendors (see Supplementary Table S2). An additional two
ompounds predicted to bind to PhzS and PhzM (triﬂuoperazine
ihydrochloride and adenosine) were also selected for testing
Fig. 1).
.2.  Effect of compounds on Pseudomonas aeruginosa viability
n  vitro
To conﬁrm that none of the drugs tested were antimicrobial (as
art of efforts to identify anti-infective drugs that would not kill
he bacteria but rather disrupt virulence), the drugs were screened
or their effect on growth of wild-type P. aeruginosa in vitro. All of
he drugs tested had little to no effect on growth of wild-type P.
eruginosa PAO1 or PA14 growth in LB broth at 37 ◦C as measured
t 600 nm (see Fig. 2C and Supplementary Fig. S1).
.3.  Inhibition of Pseudomonas aeruginosa pathogenicity by
aloxifene
The  compounds were tested for attenuated P. aeruginosa PAO1
nd PA14 virulence in the C. elegans infection model (Supplemen-
ary Fig. S1). The most notable attenuation of C. elegans killing was
bserved for raloxifene, which promoted C. elegans survival com-
ared with controls lacking raloxifene without affecting in vitro
rowth (Fig. 2A and C). The effect was dose-dependent, with
5–95% survival observed at the highest raloxifene concentration
f 100 g/mL (or 0.21 mM)  versus 20–25% survival when infected
ith wild-type PA14 with no raloxifene present (representative
xample shown in Fig. 2A). Raloxifene is an oral selective oestrogen
eceptor modulator that is used for the prevention of osteoporo-
is in post-menopausal women and for the reduction of risk ofphzB1/2  insertion mutants. Cell density was measured at a wavelength of 600 nm.
The results indicate that P. aeruginosa infection is attenuated by raloxifene, but not
due to a direct effect on the viability of P. aeruginosa as measured in vitro.
invasive breast cancer [26] and has not been previously reported
to have anti-infective properties for treatment of any infectious
disease.
Two other compounds attenuated P. aeruginosa virulence. Addi-
tion of triiodothyronine (T3), one of the two  natural thyroid
hormones, to the culture medium had little effect on P. aeruginosa
PAO1 or PA14 growth in vitro but attenuated C. elegans killing (Sup-
plementary Fig. S1) and reduced pyocyanin production (data not
shown). Oestradiol, predicted to bind PhzB2 and LpxC, exhibited
anti-infective properties but attenuated virulence to a lesser degree
than either raloxifene or T3 (see Supplementary Fig. S2). Evaluation
of the Glide docking results revealed that raloxifene binds to PhzB2
with a more favourable score than T3 or oestradiol (Supplementary
Table S2), correlating with observations that raloxifene is a more
effective inhibitor of P. aeruginosa virulence.
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Fig. 3. Wild-type Pseudomonas aeruginosa PA14 treated with raloxifene and PA14 phzB1/2 mutants show reduced pyocyanin biosynthesis. (A) Quantiﬁcation of pyocyanin
p phzB1
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ose-dependent inhibition of pyocyanin biosynthesis for P. aeruginosa PA14 trea
ultures.
.4. Treatment of Pseudomonas aeruginosa with raloxifene
educes pyocyanin production
A  quantitative chemical assay was used to measure the amount
f pyocyanin produced by P. aeruginosa PA14 in the presence
nd absence of raloxifene. Fig. 3A shows a clear reduction in
yocyanin pigment production compared with control cultures 5 h
fter addition of raloxifene, supporting the possible inhibition of
he phenazine biosynthesis pathway. The inhibition of pyocyanin
ccurred in a dose-dependent manner (Fig. 3B).
The amount of pyocyanin produced after treatment with ralox-
fene was similar to that of a PA14 mutant lacking a functional copy
f PhzB1 which results in disruption of the phenazine biosynthe-
is pathway. Pyocyanin production for the phzB1 insertion mutant
as comparable with that of P. aeruginosa treated with 100 g/mL
aloxifene (Fig. 3A). Pyocyanin production for the PA14 phzB2 inser-
ion mutant was substantially reduced.
Pyocyanin production was correlated with C. elegans survival.
orms infected with the phzB2 mutant survived longer than
orms infected with the wild-type PA14 strain (Fig. 2B). The phzB1
utant showed slightly reduced virulence for strain PA14. Analo-
ous experiments were conducted for strain PAO1. Similar effects/2 insertion mutants, with and without the addition of 100 g/mL raloxifene. (B)
ith raloxifene at the speciﬁed doses. Quantiﬁcation was performed on overnight
were  observed for raloxifene treatment and the phzB2 mutant;
however, the phzB1 mutant appeared to have a stronger effect on
survival in strain PAO1 compared with PA14 (Fig. 2B and Supple-
mentary Fig. S3).
4.  Discussion
This study investigated the possibility of repurposing existing
drugs to treat P. aeruginosa infections as well as targeting virulence
rather than essential cellular functions through an initial compu-
tational screen. Raloxifene was found to strongly protect C. elegans
against killing by P. aeruginosa PAO1 and PA14, with the effect likely
due to inhibition of phenazine biosynthesis. Pyocyanin production
is required for Pseudomonas pathogenesis in plants, and increased
levels of pyocyanin have been observed in Pseudomonas–mouse
burn  and mouse lung infection models. These observations strongly
suggest that pyocyanin is a conserved virulence factor with impor-
tant roles in the success of P. aeruginosa to infect hosts of diverse
evolutionary origin [12,27]. Thus, inhibition of pyocyanin synthe-
sis in the C. elegans model is likely to be relevant to mammalian
systems as well.
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One concern might be that computational docking is known
o have high false-positive rates; however, the similarity in the
inding sites cannot be ignored. In any case, regardless of whether
aloxifene binds to the exact location predicted using this approach,
henazine biosynthesis is clearly impacted by raloxifene treatment,
nd virulence in the C. elegans model is attenuated. Another concern
ight be that the effects observed are the result of interference with
S. Preliminary data suggest that this is not the case given that Pseu-
omonas quinolone signal (PQS), a key QS molecule that regulates
he expression of a subset of genes belonging to the QS regulon,
ncluding the phz operon [28], is not impacted by the addition of
aloxifene (Supplementary Fig. S4).
Of the 11 compounds initially selected for testing (9 with
redicted PhzB2 interactions and 2 with predicted PhzM and
hzS interactions), 3 showed promise as anti-infective drug
andidates—a success rate of 27%. This is signiﬁcantly higher and
ore efﬁcient than the 0.25% hit rate obtained from an untargeted
creen for anti-infective agents for Enterococcus faecalis [29]. The
ailure of some of the computationally predicted compounds to
ttenuate virulence is not surprising given the biases present in
electing protein binding sites as well as subjectivity inherent in
reparing molecules for molecular docking studies. However, it is
otable that the computational methods employed in this study
ccelerated the ability to identify new drug leads for P. aeruginosa.
From a practical standpoint, this represents only the ﬁrst stage
n a process to eventually demonstrate efﬁcacy for treatment
f human CF-associated infections. For example, drug delivery
echanisms and dosage levels required to be effective in the
icroaerophilic/bioﬁlm conditions that are relevant to CF remain
o be determined. It should also be appreciated that potential anti-
nfective drugs, such as those identiﬁed here, represent treatments
hat would not directly kill the bacterium, but through ‘disarming’
hem would allow the host immune system to potentially clear the
nfection without damage to the host occurring, or limit the ability
f the bacterium to gain/maintain a foothold in the host environ-
ent. However, the lack of direct killing of the bacterium should
educe selective pressure for the bacterium to develop resistance
o the drug, making such anti-infective drugs attractive as new,
otentially quite sustainable options for infectious disease control.
his study demonstrates that anti-infective activity can be found
mong existing collections of FDA-approved compounds, which
ay represent an untapped reservoir of drugs for infectious disease
ontrol.
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